Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPhA bolsters lobbying team

Executive Summary

The Generic Pharmaceutical Association appoints Gary Heimberg as VP-federal affairs and Jason Money as director of government affairs. Heimberg comes to GPhA from Akin Gump's public law and policy practice where he was a senior counsel; he has also worked for Sen. Edward Kennedy, D-Mass. Bruce Lott, who previously had the title of VP of government affairs, will serve as VP of state affairs. Prior to joining GPhA, Money served as health legislative assistant for Sen. George Allen, R-Va. He and Reilly O'Connor, who was recently promoted, will both serve as directors of government affairs...

You may also be interested in...



The Race To Vaccinate The World Against COVID-19

Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.

Innovent Expands Internationally With Indonesia Deal

Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.

Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings

Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel